Cargando…
Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine
Mesenchymal stem cells (MSCs) derived from myelodysplastic syndromes (MDSs) have been demonstrated to accelerate the progression of MDS. However, whether the phenotype of MSCs derived from MDS (MDS-MSCs) may be reversed and serve as a potential target for the treatment of MDS remains unclear. The pr...
Autores principales: | Pang, Yanbin, Geng, Suxia, Zhang, Hongyang, Lai, Peilong, Liao, Pengjun, Zeng, Lingji, Lu, Zesheng, Weng, Jianyu, Du, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781515/ https://www.ncbi.nlm.nih.gov/pubmed/31611955 http://dx.doi.org/10.3892/ol.2019.10788 |
Ejemplares similares
-
Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway
por: Xu, Ruohao, et al.
Publicado: (2023) -
Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment
por: Symeonidis, Argiris, et al.
Publicado: (2023) -
Analysis of the expression of PHTF1 and related genes in acute lymphoblastic leukemia
por: Huang, Xin, et al.
Publicado: (2015) -
Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia
por: Zhang, Lenghe, et al.
Publicado: (2022) -
Decitabine With or Without Micro-Transplantation for the Treatment of Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center Retrospective Study of 22 Patients
por: Li, MinMing, et al.
Publicado: (2021)